Development of a highly productive stable cell line to streamline recombinant adeno-associated virus (AAV) production
Having an efficient and scalable manufacturing production process of Adeno-Associated Virus (AAV) vectors remains one of the most challenging problems in the industry for meeting the high demand of AAV for clinical application in gene therapy. The current production process of AAV relies on the co-transfection of three plasmids containing the main virus structural and regulatory genes, the helper function and the gene of interest. Transient transfection of multiple plasmids is not optimal, leading to a small portion of the cells being productive. This project proposes the development of a highly productive stable cell line through cell line engineering enabling streamlined scalable AAV production.